p27 in Cell Cycle Control and Cancer

References

• Hartwell L. H., Weinert T. A. Checkpoints: controls that ensure the order of cell cycle events. Science 1989; 246: 629–634
   PubMed Web of Science ®Google Scholar
• Pines J. Cyclins, CDKs and cancer. Seminars In Cancer Biology 1995; 6: 63–72
   PubMed Web of Science ®Google Scholar
• Hunter T., Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573–582
   Google Scholar
• Strauss M., Lukas J., Bartek J. Unrestricted cell cycling and cancer. Nature Medicine 1995; 1: 1245–1246
   PubMed Web of Science ®Google Scholar
• Hartwell L. H., Kastan M. B. Cell cycle control and cancer. Science 1994; 266: 1821–1828
   PubMed Web of Science ®Google Scholar
• Sherr C. J. Cancer cell cycles. Science 1996; 114: 1672–1677
   Web of Science ®Google Scholar
• Sherr C. J., Roberts J. M. Inhibitors of mammalian Gl cyclin-dependent kinases. Genes & Development 1995; 9: 1149–1163
   PubMed Web of Science ®Google Scholar
• Pardee A. B. (1978) A restriction point for control of normal animal cell proliferation. Proceedings of the National Academy of Sciences of the United States of America 1974; 71:1286–1290. 1974
   Google Scholar
• Pardee A. B. G1 events and regulation of cell proliferation. Science 1989; 246: 603–608
   PubMed Web of Science ®Google Scholar
• Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323–330
   PubMed Web of Science ®Google Scholar
• Clurman B. E., Roberts J. M. Cell cycle and cancer. Journal of the National Cancer Institute 1995; 87: 1499–1501
   PubMed Web of Science ®Google Scholar
• Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701–704
   PubMed Web of Science ®Google Scholar
• Zhang H., Xiong Y., Beach D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Molecular Biology of the Cell 1993; 4: 897–906
   PubMed Web of Science ®Google Scholar
• Zhang H., Hannon G. J., Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes & Development 1994; 8: 1750–1758
   PubMed Web of Science ®Google Scholar
• El-Deiry W. S., Tokino X, Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–825
   PubMed Web of Science ®Google Scholar
• Gu Y., Turck C. W., Morgan D. O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory sub-unit. Nature 1993; 366: 707–710
   PubMed Web of Science ®Google Scholar
• Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805–816
   PubMed Web of Science ®Google Scholar
• Noda A., Ning Y, Venable S. R, Pereira-Smith O. M., Smith J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Experimental Cell Research 1994; 211: 90–98
   PubMed Web of Science ®Google Scholar
• Harper J. W., Elledge S. J., Keyomarsi K., Dynlacht B., Tsai L. H., Zhang P., Dobrowolski S., Bai C., Connell-Crowley L., Swindell E., Fox M. P., Wei N. Inhibition of cyclin-dependent kinases by p21. Molecular Biology of the Cell 1995; 6: 387–400
   PubMed Web of Science ®Google Scholar
• Michieli P., Li W. Q., Lorenzi M. V., Miki T, Zakut R., Givol D., Pierce J. H. Inhibition of onco-gene-mediated transformation by ectopic expression of p21Wafl in NIH3T3 cells. Oncogene 1996; 12: 775–784
   PubMed Web of Science ®Google Scholar
• Shiyanov P., Bagchi S., Adami G., Kokontis J., Hay N., Arroyo M., Morozov A., Raychaudhuri P. p21 disrupts the interaction between cdk2 and the E2F-p130 complex. Molecular & Cellular Biology 1996; 16: 737–744
   Web of Science ®Google Scholar
• Dimri G. P., Nakanishi M., Desprez P. Y., Smith J. R., Campisi J. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Molecular & Cellular Biology 1996; 16: 2987–2997
   Web of Science ®Google Scholar
• Afshari C. A., Nichols M. A., Xiong Y., Mudryj M. A role for a p21-E2F interaction during senescence arrest of normal human fibroblasts. Cell Growth & Differentiation 1996; 7: 979–988
   PubMedGoogle Scholar
• Xiong Y., Zhang H., Beach D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes & Development 1993; 7: 1572–1583
   PubMed Web of Science ®Google Scholar
• Di Leonardo A., Linke S. P., Clarkin K., Wahl G. M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cipl in normal human fibroblasts. Genes & Development 1994; 8: 2540–2551
   PubMed Web of Science ®Google Scholar
• Dulic V., Kaufmann W. K., Wilson S. J., Tlsty T. D., Lees E., Harper J. W., Elledge S. J., Reed S. I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76: 1013–1023
   PubMed Web of Science ®Google Scholar
• Brugarolas J., Chandrasekaran C., Gordon J. I., Beach D., Jacks T., Hannon G. J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995; 377: 552–557
   PubMed Web of Science ®Google Scholar
• Waldman T, Kinzler K. W., Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Research 1995; 55: 5187–5190
   PubMed Web of Science ®Google Scholar
• Del Sal G., Murphy M., Ruaro E. M., Lazarevic D., Levine A. J., Schneider C. Cyclin D1 and p21/waf1 are both involved in p53 growth suppression. Oncogene 1996; 12: 177–185
   PubMed Web of Science ®Google Scholar
• Terada Y., Tatsuka M., Jinno S., Okayama H. Requirement for tyrosine phosphorylation of Cdk4 in G1 arrest induced by ultraviolet irradiation. Nature 1995; 376: 358–362
   PubMed Web of Science ®Google Scholar
• Poon R. Y C., Jiang W., Toyoshima H., Hunter T. Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage. Journal of Biological Chemistry 1996; 271: 13283–13291
   PubMed Web of Science ®Google Scholar
• Yuan Z. M., Huang Y. Y., Whang Y, Sawyers C., Weichselbaum R., Kharbanda S., Kufe D. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature 1996; 382: 272–274
   PubMed Web of Science ®Google Scholar
• Waldman T., Lengauer C., Kinzler K. W., Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996; 381: 713–716
   PubMed Web of Science ®Google Scholar
• Deng C., Zhang P., Harper J. W., Elledge S. J., Leder P. Mice lacking p21c/w/W4F;undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675–684
   PubMed Web of Science ®Google Scholar
• Attardi L. D., Lowe S. W., Brugarolas J., Jacks T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO Journal 1996; 15: 3693–3701
   PubMed Web of Science ®Google Scholar
• Polyak K., Waldman T., He T. C., Kinzler K. W., Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes & Development 1996; 10: 1945–1952
   PubMed Web of Science ®Google Scholar
• Donehower L. A., Harvey M., Slagle B. L., McArthur M. J., Montgomery C. A., Butel J. S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215–221
   PubMed Web of Science ®Google Scholar
• Jacks T., Remington L., Williams B. O., Schmitt E. M., Halachmi S., Bronson R. T., Weinberg R. A. Tumor spectrum analysis in p5JJ-mutant mice. Current Biology 1994; 4: 1–7
   PubMed Web of Science ®Google Scholar
• Williams B. O., Remington L., Albert D. M., Mukai S., Bronson R. T., Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nature Genetics 1994; 7: 480–484
   PubMed Web of Science ®Google Scholar
• Harvey M., McArthur M. J., Montgomery C. A., Butel J. S., Bradley A., Donehower L. A. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nature Genetics 1993; 5: 225–229
   PubMed Web of Science ®Google Scholar
• Michieli P., Chedid M., Lin D., Pierce J. H., Mercer W. E., Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Research 1994; 54: 3391–3395
   PubMed Web of Science ®Google Scholar
• Macleod K. E, Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., Vogelstein B., Jacks T. p53-depend-ent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes & Development 1995; 9: 935–944
   PubMed Web of Science ®Google Scholar
• Steinman R. A., Hoffman B., Iro A., Guillouf C., Lieber-Mann D. A., E1-Houseini M. E. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994; 9: 3389–3396
   PubMed Web of Science ®Google Scholar
• Jiang H., Lin J., Su Z. Z., Collart F. R., Huberman E., Fisher P. B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1994; 9: 3397–3406
   PubMed Web of Science ®Google Scholar
• Halevy O., Novitch B. G., Spicer D. B., Skapek S. X., Rhee J., Hannon G. J., Beach D., Lassar A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995; 267: 1018–1021
   PubMed Web of Science ®Google Scholar
• Skapek S. X., Rhee J., Spicer D. B., Lassar A. B. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 1995; 267: 1022–1024
   PubMed Web of Science ®Google Scholar
• Parker S. B., Eichele G., Zhang P., Rawls A., Sands A. T., Bradley A., Olson E. N., Harper J. W., Elledge S. J. p53-independent expression of p21C1p1 in muscle and other terminally differentiating cells. Science 1995; 267: 1024–1027
   PubMed Web of Science ®Google Scholar
• Liu M., Lee M.-H., Cohen M., Bommakanti M., Freed-Man L. P. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes & Development 1996; 10: 142–153
   PubMed Web of Science ®Google Scholar
• Hall M., Bates S., Peters G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 1995; 11: 1581–1588
   PubMed Web of Science ®Google Scholar
• Pietenpol J. A., Bohlander S. K., Sato Y, Papadopoulos N., Liu B., Friedman C., Trask B. J., Roberts J. M., Kinzler K. W., Rowley J. D., Vogelstein B. Assignment of the human p27Kipl gene to 12p13 and its analysis in leukemias. Cancer Research 1995; 55: 1206–1210
   PubMed Web of Science ®Google Scholar
• Polyak K., Lee M.-H., Erdjument-Bromage H., Koff A., Roberts J. M., Tempst P., Massague J. Cloning of p27Kipl a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59–66
   PubMed Web of Science ®Google Scholar
• Slingerland J. M., Hengst L., Pan C.-H., Alexander D., Stampfer M. R., Reed S. I. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor P-arrested epithelial cells. Molecular & Cellular Biology 1994; 14: 3683–3694
   Web of Science ®Google Scholar
• Hengst L., Dulic V, Slingerland J. M., Lees E., Reed S. I. (1978) A cell cycle-related inhibitor of cyclin-dependent kinases. Proceedings of the National Academy of Sciences of the United States of America 1994; 91:5291–5295. 1994
   Google Scholar
• Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67–74
   PubMed Web of Science ®Google Scholar
• Coats S., Flanagan W. M., Nourse J., Roberts J. M. Requirement of p27 p for restriction point control of the fibroblast cell cycle. Science 1996; 272: 877–880
   PubMed Web of Science ®Google Scholar
• Polyak K., Kato J.-Y., Solomon M. J., Sherr C. J., Massague J., Roberts J. M., Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-P and contact inhibition to cell cycle arrest. Genes & Development 1994; 8: 9–22
   PubMed Web of Science ®Google Scholar
• Ewen M. E., Sluss H. K., Whitehouse L. L., Livingston D. M. TGFP inhibition of cdk4 synthesis is linked to cell cycle arrest. Cell 1993; 74: 1009–1020
   PubMed Web of Science ®Google Scholar
• Kato J. Y, Matsuoka M., Polyak K., Massague J., Sherr C. J. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27KipI) of cyclin-dependent kinase 4 activation. Cell 1994; 79: 487–496
   PubMed Web of Science ®Google Scholar
• Nourse J., Firpo E., Flanagan W. M., Coats S., Polyak K., Lee M.-H., Massague J., Crabtree G. R., Roberts J. M. Interleukin-2-mediated elimination of the p27p cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372: 570–573
   PubMed Web of Science ®Google Scholar
• Rivard N., L'Allemain G., Bartek J., Pouysségur J. Abrogation of p21Kipl by cDNA antisense suppresses quiescence (Gq state) in fibroblasts. Journal of Biological Chemistry 1996; 271: 18337–18341
   PubMed Web of Science ®Google Scholar
• Kiyokawa H., Kineman R. D., Manova-Todorova K. O., Soares V C., Hoffman E. S., Ono M., Khanam D., Hayday A- C., Frohman L. A., Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p21Kipl. Cell 1996; 85: 721–732
   PubMed Web of Science ®Google Scholar
• Fero M. L., Rivkin M., Tasch M., Porter P., Carow C. E., Firpo E., Polyak K., Tsai L. H., Broudy V., Perlmutter R. M., Kaushansky K., Roberts J. M. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27Kipl -deficient mice. Cell 1996; 85: 733–744
   PubMed Web of Science ®Google Scholar
• Pagano M, Tam S. W., Theodoras A. M., Beer-Romero P., Del Sal G., Chau V., Yew P. R., Draetta G., Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682–685
   PubMed Web of Science ®Google Scholar
• Pietenpol J. A. (1978) A commentary on the 1996 American Association for Cancer Research Meeting - “Cancer susceptibility genes and molecular carcinogenesis”. Biochimica et Biophysica Acta - Reviews on Cancer 1996; 1288:R5-R8. 1996
   Google Scholar
• Lee M.-H., Reynisdottir I., Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes & Development 1995; 9: 639–649
   PubMed Web of Science ®Google Scholar
• Matsuoka S., Edwards M. C., Bai C., Parker S., Zhang P., Baldini A., Harper J. W., Elledge S. J. p57KIP2, a structurally distinct member of the p21CIPI Cdk inhibitor family, is a candidate tumor suppressor gene. Genes & Development 1995; 9: 650–662
   PubMed Web of Science ®Google Scholar
• LaBaer J., Garrett M. D., Stevenson L. R, Slingerland J. M., Sandhu C., Chou H. S., Fattaey A., Harlow E. New functional activities for the p21 family of cdk inhibitors. Genes & Development 1997; 11: 847–862
   PubMed Web of Science ®Google Scholar
• Cheng M., Olivier P., Diehl J. A., Fero M., Roussel M. F., Roberts J. M., Sherr C. J. The p21Kip1 and p27Kip1 CDK “inhibitors” are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO Journal 1999; 18: 1571–1583
   PubMed Web of Science ®Google Scholar
• Blain S. W., Montalvo E., Massague J. Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. Journal of Biological Chemistry 1997; 272: 25863–25872
   PubMed Web of Science ®Google Scholar
• Sherr C. J., Roberts J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes & Development 1999; 13: 1501–1512
   PubMed Web of Science ®Google Scholar
• Ohtani K., DeGregori J., Nevins J. R. (1978) Regulation of the cyclin E gene by transcription factor E2F1. Proceedings of the National Academy of Sciences of the United States of America 1995; 92:12146–12150. 1995
   Google Scholar
• Geng Y., Eaton E. N., Picon M., Roberts J. M., Lundberg A. S., Gifford A., Sardet C., Weinberg R. A. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 1996; 12: 1173–1180
   PubMed Web of Science ®Google Scholar
• Sheaff R. J., Groudine M., Gordon M., Roberts J. M., Clurman B. E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes & Deveiopment 1997; 11: 1464–1478
   PubMed Web of Science ®Google Scholar
• Vlach J., Hennecke S., Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1. EMBO Journal 1997; 16: 5334–5344
   PubMed Web of Science ®Google Scholar
• Fero M. L., Randel E., Gurley K. E., Roberts J. M., Kemp C. J. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998; 396: 177–180
   PubMed Web of Science ®Google Scholar
• Ponce-Castafieda M. V., Lee M. H., Latres E., Polyak K., Lacombe L., Montgomery K., Mathew S., Krauter K., Sheinfeld J., Massague J., Cordon-Cardo C. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Research 1995; 55: 1211–1214
   PubMed Web of Science ®Google Scholar
• Spirin K. S., Simpson J. F., Takeuchi S., Kawamata N., Miller C. W., Koeffler H. P. p27/Kip1 mutation found in breast cancer. Cancer Research 1996; 56: 2400–2404
   PubMed Web of Science ®Google Scholar
• Takeuchi S., Mori N., Koike M., Slater J., Park S., Miller C. W., Miyoshi I., Koeffler H. P. Frequent loss of heterozygosity in region of the KIP1 locus in non-small cell lung cancer: evidence for a new tumor suppressor gene on the short arm of chromosome 12. Cancer Research 1996; 56: 738–740
   PubMed Web of Science ®Google Scholar
• Stegmaier K., Takeuchi S., Golub T. R., Bohlander S. K., Bartram C. R., Koeffler H. P. Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia. Cancer Research 1996; 56: 1413–1417
   PubMed Web of Science ®Google Scholar
• Hayette S., Thomas X., Bertrand Y, Tigaud I., Callanan M., Thiebaut A., Charrin C., Archimbaud E., Magaud J. P., Rimokh R. Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias. Leukemia 1997; 11: 1696–1699
   PubMed Web of Science ®Google Scholar
• Loda M., Cukor B., Tam S. W., Lavin P., Fiorentino M., Draetta G. E, Jessup J. M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Medicine 1997; 3: 231–234
   PubMed Web of Science ®Google Scholar
• Catzavelos C., Bhattacharya N., Ung Y. C., Wilson J. A., Roncari L., Sandhu C., Shaw P., Yeger H., Morava-Protzner I., Kapusta L., Franssen E., Pritchard K. I., Slingerland J. M. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. Nature Medicine 1997; 3: 227–230
   PubMed Web of Science ®Google Scholar
• Porter P. L., Malone K. E., Heagerty P. J., Alexander G. M., Gatti L. A., Firpo E. J., Daling J. R., Roberts J. M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Medicine 1997; 3: 222–225
   PubMed Web of Science ®Google Scholar
• Wu J., Shen Z. Z., Lu L. S., Jiang M., Han Q. X., Fontana J. A., Barsky S. H., Shao Z. M. Prognostic role of p27Kip1 and apoptosis in human breast cancer. British Journal of Cancer 1999; 79: 1572–1578
   PubMed Web of Science ®Google Scholar
• Tsihlias J., Kapusta L. R., DeBoer G., Morava-Protzner I., Zbieranowski I., Bhattacharya N., Catzavelos G. C., Klotz L. H., Slingerland J. M. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Research 1998; 58: 542–548
   PubMed Web of Science ®Google Scholar
• Cote R. J., Shi Y, Groshen S., Feng A. C., Cordon-Cardo C., Skinner D., Lieskovosky G. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. Journal of the National Cancer Institute 1998; 90: 916–920
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C., Koff A., Drobnjak M., Capodieci P., Osman I., Millard S. S., Gaudin P. B., Fazzari M., Zhang Z. F., Massague J., Scher H. I. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. Journal of the National Cancer Institute 1998; 90: 1284–1291
   PubMed Web of Science ®Google Scholar
• Singh S. P., Lipman J., Goldman H., Ellis F. H., Aizenman L., Cangi M. G., Signoretti S., Chiaur D. S., Pagano M., Loda M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Research 1998; 58: 1730–1735
   PubMed Web of Science ®Google Scholar
• Anayama T., Furihata M., Ishikawa T, Ohtsuki Y., Ogoshi S. Positive correlation between p27Kip1 expression and progression of human esophageal squamous cell carcinoma. International Journal of Cancer 1998; 79: 439–443
   PubMed Web of Science ®Google Scholar
• Mori M., Mimori K., Shiraishi T, Tanaka S., Ueo H., Sugimachi K., Akiyoshi T. p27 expression and gastric carcinoma. Nature Medicine 1998; 3: 593–593
   Web of Science ®Google Scholar
• Newcomb E. W, Sosnow M., Demopoulos R. I., Zeleniuch-Jacquotte A., Sorich J., Speyer J. L. Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. American Journal of Pathology 1999; 154: 119–125
   PubMed Web of Science ®Google Scholar
• Catzavelos C., Tsao M. S., DeBoer G., Bhattacharya N., Shepherd F. A., Slingerland J. M. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of ras. Cancer Research 1999; 59: 684–688
   PubMed Web of Science ®Google Scholar
• Lu C. D., Morita S., Ishibashi T., Hara H., Isozaki H., Tanigawa N. Loss of p27Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma. Cancer 1999; 85: 1250–1260
   PubMed Web of Science ®Google Scholar
• Flørenes V. A., Mslandsmo G. M, Kerbel R. S., Slingerland J. M., Nesland J. M., Holm R. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: Inverse correlation with disease-free survival. American Journal of Pathology 1998; 153: 305–312
   PubMed Web of Science ®Google Scholar
• Erlanson M., Portin C., Linderholm B., Lindh J., Roos G., Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas: prognostic implications. Blood 1998; 92: 770–777
   PubMed Web of Science ®Google Scholar
• Møller M. B., Skjødt K., Mortensen L. S., Pedersen N. T. Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: independent prognostic value of p27Kip1. British Journal of Haematology 1999; 105: 730–736
   PubMed Web of Science ®Google Scholar
• Saez A. I., Sanchez E., Sanchez-Beato M., Cruz M. A., Chacon I., Munoz E., Camacho F. I., Martinez-Montero J. C., Mollejo M., Garcia J. F., Piris M. A. p27Kip1 is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome. British Journal of Cancer 1999; 80: 1427–1434
   PubMed Web of Science ®Google Scholar
• Shiohara M., El-Deiry W. S., Wada M, Nakamaki T., Takeuchi S., Yang R., Chen D.-L., Vogelstein B., Koeffler H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781–3784
   PubMed Web of Science ®Google Scholar
• Bhatia K., Fan S., Spangler G., Weintraub M., O'Connor P. M, Judde J. G., Magrath I. A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Research 1995; 55: 1431–1435
   PubMed Web of Science ®Google Scholar
• Balbin M., Hannon G. J., Pendas A. M., Ferrando A. A., Vizoso F, Fueyo A., López-Otin C. Functional analysis of a p21WAF1,C1P1,SD11 mutant (Arg94 Trp) identified in a human breast carcinoma - evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases. Journal of Biological Chemistry 1996; 271: 15782–15786
   PubMed Web of Science ®Google Scholar
• Vidal M. J., Loganzo F, de Oliveira A. R., Hayward N. K., Albino A. P. Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Research 1995; 5: 243–250
   PubMed Web of Science ®Google Scholar
• Bullrich F, MacLachlan T. K., Sang N., Druck T., Veronese M. L., Allen S. L., Chiorazzi N., Koff A., Heubner K., Croce C. M., Giordano A. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. Cancer Research 1995; 55: 1199–1205
   PubMed Web of Science ®Google Scholar
• Kawamata N., Morosetti R., Miller C. W., Park D., Spirin K. S., Nakamaki T., Takeuchi S., Hatta Y., Simpson J., Wilc-Zynski S., Lee Y. Y., Bartram C., Koeffler H. P. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Research 1995; 55: 2266–2269
   PubMed Web of Science ®Google Scholar
• Hatada I., Ohashi H., Fukushima Y., Kaneko Y, Inoue M., Komoto Y, Okada A., Ohishi S., Nabetani A., Morisaki H., Nakayama M., Niikawa N., Mukai T. An imprinted gene p57K1P2 is mutated in Beckwith-Wiedemann syndrome. Nature Genetics 1996; 14: 171–173
   PubMed Web of Science ®Google Scholar
• Lee M. P., DeBaun M., Randhawa G., Reichard B. A., Elledge S. J., Feinberg A. P. Low frequency of p57KIP2 mutation in Beckwith-Wiedemann-syndrome. American Journal of Human Genetics 1997; 61: 304–309
   PubMed Web of Science ®Google Scholar
• Hatada I., Nabetani A., Morisaki H., Xin Z. H., Ohishi S., Tonoki H., Niikawa N., Inoue M., Komoto Y, Okada A., Steichen E., Ohashi H., Fukushima Y., Nakayama M., Mukai T. New p57KIP2 mutations in Beckwith-Wiedemann syndrome. Human Genetics 1997; 100: 681–683
   PubMed Web of Science ®Google Scholar
• Sanchez-Beato M., Saez A. I., Martinez-Montero J. C., Mateo M. S., Sanchez-Verde L., Villuendas R., Troncone G., Piris M. A. Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue. p27KIP1 expression is inversely proportional to the proliferative index. American Journal of Pathology 1997; 151: 151–160
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez L., Thieblemont C., Fend F, Kumar S., Pinyol M., Campo E., Jaffe E. S., Raffeld M. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. American Journal of Pathology 1998; 153: 175–182
   PubMed Web of Science ®Google Scholar
• Sanchez-Beato M., Camacho F. I., Martinez-Montero J. C., Saez A. I., Villuendas R., Sanchez-Verde L., Garcia J. F., Piris M. A. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. Blood 1999; 94: 765–772
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez L., Davies-Hill T., Sorbara L., Jaffe E. S., Raffeld M. Loss of detectable p27 protein expression in mantle cell lymphomas (MCL) is a result of its sequestration by cyclin D1: implications for pathogenesis. Blood 1999; 92: 314a
   Web of Science ®Google Scholar
• Vrhovac R., Delmer A., Tang R., Marie J. P., Zittoun R., Ajchenbaum-Cymbalista F. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood 1998; 91: 4694–4700
   PubMed Web of Science ®Google Scholar